Business
KetamineOne Adds Seattle Location to US Clinical Network
KetamineOne Adds Seattle Location to US Clinical Network.
About this update from Wellbeing Digital Sciences Inc.
[{"type":"text","content":"\n VANCOUVER, British Columbia, Dec. 08, 2021 (GLOBE NEWSWIRE) -- KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that it has been engaged by Dr. Tami Meraglia to establish a ketamine infusion clinic in Seattle, Washington. The new clinic will operate as Seattle Ketamine Infusions (“SKI” or the “Clinic”) and be located at 311 West Republican Street. Dr. Meraglia is focused on the areas of personalized intravenous (“IV”) treatments and is also a national best-selling author and frequent media guest regarding total health and wellness topics. Ketamine One will provide training, protocol development, and ongoing support for the Clinic, with the first patient treatments expected at SKI in early 2022. Management Commentary “Helping Dr. Tami set up and open a ketamine clinic in the Seattle market is an exciting project for Ketamine One. We are looking forward to sharing our expertise and support, while also gaining from Dr. Tami’s ability to engage with a large national audience,” said Adam Deffett, Interim CEO of Ketamine One. “Ketamine One continues to move closer to achieving its goal of becoming a leader in the mental health space across North America. By establishing great relationships with medical experts in new markets, such as Seattle, our ability to transfer knowledge is increasing and that is all for the benefit of patients,” added Mr. Deffett. ABOUT KETAMINE ONE KetamineOne Capital Limited (formerly Myconic Capital Corp.) is a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments. It is working to provide the critical infrastructure needed to develop and deliver breakthrough mental health treatments. Currently, Ketamine One has a network of clinics across North America, with plans to further consolidate the highly fragmented industry. KGK Science Inc. is the Company’s wholly owned contract research division, which places it at the forefront of premium clinical research based on the subsidiary’s history and extensive experience in pharmaceuticals, cannabis, and the emerging psy...